{
  "id": 19218570,
  "title": "Rafael Holdings at Guggenheim conference touts npc drug despite trial miss",
  "url": "https://urgent.news/2026/11/09/rafael-holdings-at-guggenheim-conference-touts-npc-drug-despite-trial",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-09T21:03:26.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/transcripts/rafael-holdings-at-guggenheim-conference-touts-npc-drug-despite-trial-miss-93CH-5013165"
  },
  "original_language": "en",
  "account": "On 09 November 2026, Rafael Holdings (RFL) addressed its prospects for the drug remibetadex at the 3rd Annual Guggenheim Healthcare Innovation Conference. The company announced the successful completion of a Phase III study, an FDA filing, and a potential commercial strategy for the treatment of Niemann-Pick type C (NPC), a rare genetic disorder with both neurological and visceral symptoms. Despite the trial falling short of its primary endpoint, Rafael maintains that the pre-specified covariate analysis and other data support the filing. With just over $22 million in cash at the end of July 2025, the company anticipates enduring until the FDA's decision window in December 2025. The stock, currently trading at $1.09, has seen a 4.81% increase from the previous close of $1.04. However, it is trading at 10% above its 52-week low, reflecting a challenging year for shareholders who have experienced a 19% decrease over the past year and an 18.75% decline in just six months.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}